197 related articles for article (PubMed ID: 21918192)
1. IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.
Coursey TG; Chen PW; Niederkorn JY
J Immunol; 2011 Oct; 187(8):4219-28. PubMed ID: 21918192
[TBL] [Abstract][Full Text] [Related]
2. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
Dace DS; Chen PW; Alizadeh H; Niederkorn JY
J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.
Dace DS; Chen PW; Niederkorn JY
Immunology; 2008 Mar; 123(3):367-77. PubMed ID: 17944931
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
Dace DS; Chen PW; Niederkorn JY
J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
[TBL] [Abstract][Full Text] [Related]
5. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
Ligocki AJ; Brown JR; Niederkorn JY
J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
[TBL] [Abstract][Full Text] [Related]
6. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
[TBL] [Abstract][Full Text] [Related]
7. IFN-γ-independent intraocular tumor rejection is mediated by a macrophage-dependent process that leaves the eye intact.
Coursey TG; Chen PW; Niederkorn JY
J Leukoc Biol; 2012 Nov; 92(5):939-50. PubMed ID: 22693246
[TBL] [Abstract][Full Text] [Related]
8. Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.
Coursey TG; Chen PW; Niederkorn JY
Cancer Res; 2011 Apr; 71(7):2445-54. PubMed ID: 21307132
[TBL] [Abstract][Full Text] [Related]
9. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
10. IL-12 administered in vivo to young and aged mice. Discrepancy between the effects on tumor growth in vivo and cytotoxic T lymphocyte generation ex vivo: dependence on IFN-gamma.
Horvath-Arcidiacono JA; Mostowski HS; Bloom ET
Int Immunol; 1996 May; 8(5):661-73. PubMed ID: 8671653
[TBL] [Abstract][Full Text] [Related]
11. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
[TBL] [Abstract][Full Text] [Related]
12. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions.
Bishop DK; Chan Wood S; Eichwald EJ; Orosz CG
J Immunol; 2001 Mar; 166(5):3248-55. PubMed ID: 11207279
[TBL] [Abstract][Full Text] [Related]
13. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
14. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
[TBL] [Abstract][Full Text] [Related]
15. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma.
Kelchtermans H; Schurgers E; Geboes L; Mitera T; Van Damme J; Van Snick J; Uyttenhove C; Matthys P
Arthritis Res Ther; 2009; 11(4):R122. PubMed ID: 19686583
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2,3-deoxygenase.
Lee J; Lee J; Park MK; Lim MA; Park EM; Kim EK; Yang EJ; Lee SY; Jhun JY; Park SH; Kim HY; Cho ML
PLoS One; 2013; 8(4):e60900. PubMed ID: 23613752
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of mouse interleukin-17 bioactivity inhibits corneal allograft rejection.
Chen X; Zhao S; Tang X; Ge H; Liu P
Mol Vis; 2011; 17():2148-56. PubMed ID: 21850190
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response.
Apte SH; Groves P; Olver S; Baz A; Doolan DL; Kelso A; Kienzle N
J Immunol; 2010 Jul; 185(2):998-1004. PubMed ID: 20562261
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
20. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma.
Braun MY; Desalle F; Le Moine A; Pretolani M; Matthys P; Kiss R; Goldman M
Eur J Immunol; 2000 May; 30(5):1290-6. PubMed ID: 10820374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
